AspenBio Pharma, Inc. to Present at the Canaccord Adams 29th Annual Global Growth Conference

CASTLE ROCK, CO--(Marketwire - July 30, 2009) - AspenBio Pharma, Inc. (NASDAQ: APPY), an emerging bio-science company dedicated to the development of novel diagnostics and drugs for humans and animals, has been invited to present at the Canaccord Adams 29th Annual Global Growth Conference. The conference will be held at the InterContinental Boston on August 11-13, 2009.

Company management is scheduled to present on Tuesday, August 11, 2009 at 8:00 a.m. Eastern Time with one-on-one meetings held throughout the day. Management will discuss the company’s progress including its recently filed Premarket Notification [510(k)] with the U.S. Food and Drug Administration for its AppyScore Test, the first blood-based test designed as an aid in the diagnosis of human appendicitis.

For more information about the conference or to schedule a one-on-one meeting with the company, contact your Canaccord Adams institutional sales representative.

About Canaccord Adams, Inc.

Canaccord Adams is a leading independent financial services firm committed to fostering the entrepreneurial economy by bringing corporate and institutional clients a unique perspective on global investment opportunities. With operations in research, sales and trading, and investment banking, its 225 professionals seek out emerging opportunities in key sectors -- mining and metals, energy, technology, life sciences, consumer, real estate, sustainability and infrastructure. Located in ten offices internationally, its experienced team generates focused, actionable ideas that identify opportunity and facilitate growth. Canaccord Adams, the international capital markets division of Canaccord Capital Inc., has operations in Toronto, London, Boston, Vancouver, New York, Calgary, San Francisco, and Houston. More information is available at www.canaccordadams.com.

About AspenBio Pharma, Inc.

AspenBio Pharma’s mission is to be a leader in the development and commercialization of innovative products that address unmet diagnostic and therapeutic needs in both Human and Animal Health. Our Human Health Division is addressing the difficult challenge of diagnosing appendicitis in the hospital emergency department setting. Our Animal Health Division is focused on therapeutic proteins that support reproductive efficiency in non-companion animals of economic importance. For more information, go to www.aspenbiopharma.com.